Viewing Study NCT05957757

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 6:37 PM
Ignite Modification Date: 2026-01-28 @ 6:02 PM
Study NCT ID: NCT05957757
Status: RECRUITING
Last Update Posted: 2023-08-31
First Post: 2023-05-12
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression
Sponsor: RenJi Hospital
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Non-Muscle Invasive Bladder Cancer View
None HER2 View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Non-Muscle Invasive Bladder Cancer View
None HER2 expression View
None BCG Failure View
None Unsuitable or refused to radical cystectomy View